The Reversal
The German government withdrew planned pharmaceutical rebate amendments in early 2025, according to industry reports. The draft proposed that pharmaceutical companies pay dynamic mandatory rebates on medicines, with rates tied to revenue and market conditions. Pfizer, Eli Lilly, Boehringer Ingelheim, and AstraZeneca publicly announced they would review or suspend planned investments in Germany. The government struck the passage from the draft bill. The entire process took three weeks.
The reversal is not a victory for the pharma lobby but a symptom. Companies invest where they can calculate costs for the next five to ten years. Regulation only becomes a location factor when it remains predictable. A draft that vanishes within weeks under pressure signals the opposite. The industry now publicly calls the German system unpredictable.
What Denmark Does Differently
Denmark reformed pharmaceutical price regulation in 2019. The Danish Medicines Agency published the draft in January 2018, set a six-month public consultation period, and established a five-year implementation horizon. Pharmaceutical companies knew in spring 2018 which rebate structures would apply from 2023 onward. Investment commitments from pharmaceutical companies increased significantly during this period.
The difference does not lie in the severity of regulation. Denmark also demands rebates, sometimes higher than Germany. The difference lies in lead time. Companies can make location decisions, plan production lines, allocate research budgets. The Danish state regulates, but it does so with advance notice. This creates trust not in the state's benevolence but in its calculability.
The Cost of Unpredictability
Germany made multiple major changes to pharmaceutical market regulation between 2020 and 2024. Three were withdrawn or significantly weakened after drafting but before taking effect. The average time between draft and withdrawal was typically two months or less. Industry sources indicate companies now factor significant risk buffers into regulatory cost planning for Germany because the reliability of announcements has declined.
This is not a question of political direction. Regulation can be strict or liberal. What matters is that it is announced, consulted, and then enforced. A state that publishes drafts and withdraws them under pressure loses credibility not only with the affected industry. It loses it with all industries subject to regulation. The pharma reversal sends a signal to the automotive industry, the chemical industry, the energy sector: announcements in Germany are opening bids for negotiation, not planning foundations.
Trust as a Location Factor
Location competition is often discussed as tax competition. Denmark's lower corporate tax rate (approximately 22% vs. Germany's 30%) is frequently cited. Yet the Danish pharmaceutical industry is growing faster. The reason lies not in the tax burden but in the regulatory burden—more precisely, in the predictability of regulation. A company can calculate with high taxes. It cannot calculate with a state that drafts laws, announces them, and withdraws them under pressure.
The German government did not withdraw the rebate regulation out of insight but because four corporations credibly threatened investment withdrawal. This is not a negotiation success for industry but a structural problem of the state. A capable state announces regulation with lead time, consults affected parties, adjusts the draft, and then enforces it. A hesitant state drafts, announces, comes under pressure, and withdraws. The first state gains trust, the second loses it.
What Remains
The pharma reversal is not an isolated case. It joins a chain of announcements that vanished under pressure: the car toll, the property tax reform in its original form, the solidarity surcharge abolition with delays, the Building Energy Act amendment with three postponements. The pattern is always the same: draft, resistance, withdrawal or dilution. This costs not only credibility but also money. Companies that do not know which rules will apply in five years invest elsewhere or factor in risk buffers. Both harm the location.
Regulatory predictability is not a luxury but a basic condition for long-term investment. Denmark shows it is possible. Germany shows that its absence has measurable costs. The state does not owe business low taxes or gentle regulation. It owes it reliability.
Band 1 "Freistaat" describes how the loss of trust in state capacity emerges and why announcements without enforcement are the opposite of governing.